Christopher J Schwartz
Overview
Explore the profile of Christopher J Schwartz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Pareja F, Bhargava R, Borges V, Brogi E, Canas Marques R, Cardoso F, et al.
NPJ Breast Cancer
. 2025 Jan;
11(1):6.
PMID: 39856067
Special histologic subtypes of breast cancer (BC) exhibit unique phenotypes and molecular profiles with diagnostic and therapeutic implications, often differing in behavior and clinical trajectory from common BC forms. Novel...
3.
Ramalingam K, Woody R, Glencer A, Schwartz C, Mori H, Wong J, et al.
JAMA Oncol
. 2025 Jan;
PMID: 39821301
Importance: Intratumoral immunotherapy that leverages the biological characteristics of high-risk ductal carcinoma in situ (DCIS) may be able to reduce the extent of surgical treatment and provide an alternative approach...
4.
Schwartz C, Krings G
Semin Diagn Pathol
. 2024 Oct;
41(6):272-284.
PMID: 39389890
Salivary gland-like tumors of the breast are rare neoplasms that share morphologic, immunophenotypic, and/or genetic features with their salivary gland counterparts, highlighting a shared underlying histopathogenesis in most cases. Salivary...
5.
Ye J, Theparee T, Bean G, Rutland C, Schwartz C, Vohra P, et al.
Mod Pathol
. 2024 Aug;
37(12):100593.
PMID: 39154782
The differential diagnosis of malignant spindle cell neoplasms in the breast most frequently rests between malignant phyllodes tumor (MPT) and metaplastic carcinoma (MBC). Diagnosis of MPT can be challenging due...
6.
Schwartz C, Marra A, Selenica P, Gazzo A, Tan K, Ross D, et al.
Mod Pathol
. 2024 Jun;
37(8):100541.
PMID: 38897452
Genetic alterations in the retinoblastoma susceptibility gene (RB1) are present in up to 40% of triple-negative breast cancers (BCs) and frequent in tumors with neuroendocrine differentiation, including small cell neuroendocrine...
7.
Schwartz C, Khorsandi N, Blanco A, Mukhtar R, Chen Y, Krings G
Breast Cancer Res Treat
. 2023 Dec;
204(1):171-179.
PMID: 38091153
Purpose: Germline pathogenic variants in checkpoint kinase 2 (CHEK2) are associated with a moderately increased risk of breast cancer (BC). The spectrum of clinicopathologic features and genetics of these tumors...
8.
Schwartz C, Krings G, Chen Y
Histopathology
. 2023 Sep;
84(2):409-411.
PMID: 37706238
A malignant neoplasm with spindle cell and chondroid differentiation in the breast, metastatic to lymph node. In this context, a metaplastic carcinoma is typically favored given the exceptional nature of...
9.
Shamir E, Bean G, Schwartz C, Vohra P, Wang A, Allard G, et al.
Mod Pathol
. 2023 Sep;
36(12):100324.
PMID: 37660928
Adenoid cystic carcinoma (AdCC) is a rare triple-negative breast cancer analogous to its extramammary counterparts. Diagnosis of the more aggressive solid-basaloid variant of AdCC (SB-AdCC) can be challenging due to...
10.
Clelland E, Rothschild H, Patterson A, Molina-Vega J, Kaur M, Fraser Symmans W, et al.
Breast Cancer Res Treat
. 2023 Jul;
202(2):367-375.
PMID: 37500962
Purpose: Recent guidelines defined a new reporting category of ER-low-positive breast cancer based on immunohistochemistry (IHC). While low positivity of either hormone receptor is uncommon in invasive lobular carcinoma (ILC),...